McDermott Advises Claris Ventures on Repron Therapeutics' Seed Round - McDermott Will & Emery

McDermott Advises Claris Ventures on Repron Therapeutics’ Seed Round

Overview


International law firm McDermott Will & Emery advised Claris Ventures on a EUR 2 million seed funding round for Repron Therapeutic, a biotech startup supporting the development of an epigenetic platform aimed at silencing oncogene networks for the suppression of tumor recurrence in various oncology indications.

The investment was led by Claris Ventures, while Ospedale San Raffaele and Consiglio Nazionale delle Ricerche have granted the startup with relevant patents.

The McDermott team advising Claris Ventures was led by Milan-based corporate partner Ettore Scandale, supported by associate Stefano Pardini and trainees Francesco Carrà and Carlo Serranò.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

Media Contacts